Yuichiro Ogura1, Tomohiro Iida2, Won Ki Lee3, Chui Ming Gemmy Cheung4,5, Paul Mitchell6, Sergio Leal7, Thomas Schmelter8, Tatsuro Ishibashi9. 1. Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. ogura.yuichiro@me.com. 2. Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan. 3. Nune Eye Hospital, Seoul, South Korea. 4. Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore. 5. Duke-NUS, National University of Singapore, Singapore, Singapore. 6. University of Sydney, Westmead Institute for Medical Research, Sydney, Australia. 7. Bayer Consumer Care AG, Basel, Switzerland. 8. Bayer Pharmaceuticals, Berlin, Germany. 9. Department of Ophthalmology, Kyushu University, Fukuoka, Japan.
Abstract
PURPOSE: To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) versus IVT-AFL plus rescue photodynamic therapy (IVT-AFL + rPDT) in the subgroup of Japanese patients with polypoidal choroidal vasculopathy (PCV) enrolled in the PLANET study. STUDY DESIGN: A 96-week, double-masked, sham-controlled phase-3b/4 randomized clinical trial conducted at multiple centers from May 2014 to August 2016. PATIENTS AND METHODS: Patients with PCV (BCVA 73-24 ETDRS letters [20/40-20/320 Snellen]) received 3 initial monthly doses of IVT-AFL 2 mg. At week 12, the patients were randomly assigned 1:1 to IVT-AFL + sham PDT or IVT-AFL + rPDT. Patients not requiring rescue received IVT-AFL every 8 weeks; those requiring rescue received IVT-AFL monthly plus sham/active PDT. Following week 52, the treatment intervals could be extended > 8 weeks. RESULTS: The baseline demographics for the 159 Japanese patients were balanced. At week 96, the mean BCVA change was + 9.7 (IVT-AFL) versus + 9.5 letters (IVT-AFL + rPDT) (least-squares mean difference of - 0.3; 95% CI, - 3.7 to 3.1); the mean central subfield thickness reduction was - 148.0 µm versus - 145.9 µm. Overall, 17.1% of the patients required rescue PDT. At week 96, 25.0% (IVT-AFL) and 37.9% (IVT-AFL + rPDT) of the patients had complete polyp regression; 84.1% (IVT-AFL) and 88.4% (IVT-AFL + rPDT) of the patients had no evidence of active polyps. The mean number of injections (weeks 52-96) were 4.6 (IVT-AFL) and 4.5 (IVT-AFL + rPDT). Overall, 36.0% (IVT-AFL) and 33.8% (IVT-AFL + rPDT) of the patients experienced ocular treatment-emergent adverse events. CONCLUSION:IVT-AFL monotherapy was efficacious for the treatment of Japanese patients with PCV, and the addition of rescue PDT did not show additional benefits.
RCT Entities:
PURPOSE: To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) versus IVT-AFL plus rescue photodynamic therapy (IVT-AFL + rPDT) in the subgroup of Japanese patients with polypoidal choroidal vasculopathy (PCV) enrolled in the PLANET study. STUDY DESIGN: A 96-week, double-masked, sham-controlled phase-3b/4 randomized clinical trial conducted at multiple centers from May 2014 to August 2016. PATIENTS AND METHODS: Patients with PCV (BCVA 73-24 ETDRS letters [20/40-20/320 Snellen]) received 3 initial monthly doses of IVT-AFL 2 mg. At week 12, the patients were randomly assigned 1:1 to IVT-AFL + sham PDT or IVT-AFL + rPDT. Patients not requiring rescue received IVT-AFL every 8 weeks; those requiring rescue received IVT-AFL monthly plus sham/active PDT. Following week 52, the treatment intervals could be extended > 8 weeks. RESULTS: The baseline demographics for the 159 Japanese patients were balanced. At week 96, the mean BCVA change was + 9.7 (IVT-AFL) versus + 9.5 letters (IVT-AFL + rPDT) (least-squares mean difference of - 0.3; 95% CI, - 3.7 to 3.1); the mean central subfield thickness reduction was - 148.0 µm versus - 145.9 µm. Overall, 17.1% of the patients required rescue PDT. At week 96, 25.0% (IVT-AFL) and 37.9% (IVT-AFL + rPDT) of the patients had complete polyp regression; 84.1% (IVT-AFL) and 88.4% (IVT-AFL + rPDT) of the patients had no evidence of active polyps. The mean number of injections (weeks 52-96) were 4.6 (IVT-AFL) and 4.5 (IVT-AFL + rPDT). Overall, 36.0% (IVT-AFL) and 33.8% (IVT-AFL + rPDT) of the patients experienced ocular treatment-emergent adverse events. CONCLUSION:IVT-AFL monotherapy was efficacious for the treatment of Japanese patients with PCV, and the addition of rescue PDT did not show additional benefits.
Authors: Maria Eleftheriadou; Clara Vazquez-Alfageme; Cristina Maria Citu; Roxanne Crosby-Nwaobi; Sobha Sivaprasad; Philip Hykin; Robin D Hamilton; Praveen J Patel Journal: Am J Ophthalmol Date: 2016-10-14 Impact factor: 5.258
Authors: Ursula Schmidt-Erfurth; Peter K Kaiser; Jean-François Korobelnik; David M Brown; Victor Chong; Quan Dong Nguyen; Allen C Ho; Yuichiro Ogura; Christian Simader; Glenn J Jaffe; Jason S Slakter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Olaf Sowade; Oliver Zeitz; Christiane Norenberg; Rupert Sandbrink; Jeffrey S Heier Journal: Ophthalmology Date: 2013-09-29 Impact factor: 12.079
Authors: Maria Eleftheriadou; Maria Gemenetzi; Marko Lukic; Sobha Sivaprasad; Philip G Hykin; Robin D Hamilton; Ranjan Rajendram; Adnan Tufail; Praveen J Patel Journal: Ophthalmol Ther Date: 2018-07-07
Authors: Frank G Holz; Ramin Tadayoni; Stephen Beatty; Alan Berger; Matteo G Cereda; Rafael Cortez; Carel B Hoyng; Philip Hykin; Giovanni Staurenghi; Stephanie Heldner; Timon Bogumil; Theresa Heah; Sobha Sivaprasad Journal: Br J Ophthalmol Date: 2014-09-05 Impact factor: 4.638
Authors: Frank G Holz; Ramin Tadayoni; Stephen Beatty; Alan Berger; Matteo Giuseppe Cereda; Philip Hykin; Giovanni Staurenghi; Kim Wittrup-Jensen; Andreas Altemark; Jonas Nilsson; Kun Kim; Sobha Sivaprasad Journal: Br J Ophthalmol Date: 2016-03-30 Impact factor: 4.638